

Human FXI Protein

Cat. No. FXI-HM101

Description

Source	Recombinant Human FXI Protein is expressed from Expi293 with His tag at the C-terminal. It contains Glu19-Val625.
Accession	P03951-1
Molecular Weight	The protein has a predicted MW of 69.1 kDa. Due to glycosylation, the protein migrates to 70-80 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

Formulation and Storage

Formulation	Supplied as 0.22µm filtered solution in PBS (pH 7.4). Please dilute to the desired concentration according to the concentration of the solution shown on the product label.
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please do not repeated freeze-thaw cycles.

Background

Coagulation factor (F)XI has been described as a component of the early phase of the contact pathway of blood coagulation, acting downstream of factor XII. In contrast to its mild hemostatic activities, FXI is known to play a significant role in thrombosis, as it is a demonstrated independent risk factor for deep vein thrombosis, ischemic stroke, and myocardial infarction. A better understanding of the varied and complex role of FXI in both thrombosis and hemostasis will help to allow better prediction of bleeding risk in FXI-deficient patients and also informing the development of targeted agents to inhibit the thrombotic activities of FXI while preserving hemostasis.


Assay Data

Tris-Bis PAGE



Human FXI on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human FXI is greater than 95% as determined by SEC-HPLC.